Could shorter cancer drug infusions be just as safe?
NCT ID NCT06031233
First seen May 02, 2026 · Last updated May 12, 2026 · Updated 1 time
Summary
This study looks at whether giving certain cancer immunotherapy drugs over a shorter time is still safe. About 776 adults starting treatment with drugs like nivolumab or pembrolizumab will have their infusion times gradually shortened if they tolerate it well. The main goal is to see if this approach keeps the risk of infusion reactions low, potentially making treatment more convenient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Isala Hospital
RECRUITINGZwolle, 8025AB, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.